Pfizer Strikes a $500 Million Deal to Block Disease Proteins Before They Are Even Made

Pfizer has signed a research collaboration and licensing deal potentially worth more than $500 million with Enodia Therapeutics, a French biotech built on research from the Institut Pasteur. The goal is to discover small-molecule drugs that act on Sec61, a piece of cellular machinery that many disease-causing proteins must pass through. The deal was announced on October 14, 2026.

The deal

Enodia receives an upfront fee and is eligible for research, development and sales milestone payments, plus tiered royalties on future sales; the individual amounts were not disclosed. Enodia will lead early discovery, identifying and refining drug candidates against several targets. Once candidates are selected, Pfizer takes over clinical trials, manufacturing, regulatory filings and commercialization.

What Sec61 is

Cells make many of their proteins — hormones, antibodies, receptors on the cell surface, and signaling molecules released into the blood — on the surface of an internal compartment called the endoplasmic reticulum. To reach their destination, these proteins are threaded through a channel in its membrane as they are being built. That channel is the Sec61 translocon. Roughly a third of all human proteins pass through it, including many that drive disease.

Stopping proteins at the source

Most drugs work by blocking a protein after it has been made, for example with an antibody that binds a receptor or a pill that jams an enzyme. Sec61 offers another option: prevent the harmful protein from being produced in usable form at all. If its passage through the channel is blocked, the half-made protein is sent for disposal. Enodia describes this as targeted protein degradation at synthesis.

The selectivity challenge

The obvious risk is that shutting the gate entirely would be catastrophic, since cells depend on Sec61 for thousands of essential proteins. Natural compounds that block it broadly are highly toxic. The key insight behind this field is that some molecules can block Sec61 selectively, stopping only certain proteins depending on the sequence at their leading end, while letting most others through. Enodia combines machine learning, structural data from cryo-electron microscopy, proteomics and custom cell lines to design such selective inhibitors across several chemical families. As chief executive Yves Ribeill put it, the company has built a broad platform for selective Sec61 modulation.

How it compares with other approaches

Sec61 inhibition joins a crowded field of efforts to get rid of unwanted proteins. PROTACs and molecular glues tag finished proteins for destruction by the cell’s disposal machinery. RNA interference and antisense drugs destroy the messenger RNA so the protein is never made, but they are injected and, outside the liver, hard to deliver. Sec61 inhibitors sit in between: they act during manufacture, and because they are small molecules they could be taken as pills and reach many tissues. The trade-off is that they only work on proteins that use this particular channel, which rules out most proteins that stay inside the cell.

What it could treat

Enodia’s own programs focus on immunology, oncology and inflammation, with potential in viral infections, since many viruses rely on the same machinery to make their proteins. In immunology, a selective Sec61 inhibitor could, in principle, block an inflammatory signaling protein or receptor in a pill rather than an injected antibody. In cancer, it could block proteins that tumors depend on. The approach is not entirely new: other companies have taken Sec61 inhibitors into early clinical trials in cancer, which suggests the target can be drugged, though none has yet been approved.

Why Pfizer is interested

Pfizer faces large patent expirations later this decade and has been rebuilding its pipeline through acquisitions and partnerships. Deals like this one are relatively small bets on new ways of making drugs, which could yield candidates against targets that conventional drugs struggle to reach. It follows Pfizer’s agreement earlier in 2026 to bring the AI platform of Chai Discovery into its research, part of a wider push to use computation to speed early discovery.

The France connection

Enodia was created through Argobio Studio, a French venture builder that turns academic discoveries into startups. Its roots at the Institut Pasteur in Paris, one of Europe’s leading biomedical research centers, illustrate a growing pipeline of European academic science into big-pharma deals, at a time when much of the industry’s dealmaking attention has shifted toward China.

The caveats

This is discovery-stage work: no Enodia drug is in clinical trials, and the deal covers molecules that have not yet been chosen. The headline value is mostly contingent on milestones that may never be reached. And the central scientific question — whether Sec61 can be blocked selectively enough to be safe for long-term use in chronic diseases — has not yet been answered in people.

What it means

For patients, nothing changes soon. For the industry, the deal is another sign that big companies are looking for drugs that act earlier in a protein’s life — at the level of genes, RNA, or now the moment of synthesis — rather than only blocking finished proteins. This is business news, not investment or medical advice.